Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.36 |
| ▸ | NOS1 | P29475 | 2/20 | 0.36 |
| ▸ | NOS2 | P35228 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12629173 | 1.00 | NOS3 (0.36) | NOS3NOS1NOS2MAPK1MEN1 | |
| SCHEMBL6437994 | 1.00 | NOS3 (0.36) | NOS3NOS1NOS2MAPK1MEN1 | |
| SCHEMBL6442259 | 1.00 | NOS3 (0.36) | NOS3NOS1NOS2MAPK1MEN1 | |
| SCHEMBL1934068 | 0.87 | BRD4 (0.33) | NOS3NOS1NOS2MEN1KMT2A | |
| SCHEMBL1934066 | 0.87 | BRD4 (0.33) | NOS3NOS1NOS2MEN1KMT2A | |
| SCHEMBL1933580 | 0.87 | BRD4 (0.33) | NOS3NOS1NOS2MEN1KMT2A | |
| SCHEMBL6440814 | 0.87 | NOS1 (0.39) | NOS3NOS1NOS2 | |
| SCHEMBL1933577 | 0.87 | BRD4 (0.33) | NOS3NOS1NOS2MEN1KMT2A | |
| SCHEMBL6438530 | 0.87 | NOS1 (0.39) | NOS3NOS1NOS2 | |
| SCHEMBL27873411 | 0.87 | NOS3 (0.30) | NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377921-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2013-02-19 | — | — | US | disclosed |
| US-20110257155-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-10-20 | — | — | US | disclosed |
| WO-1991013616-A1 | NOVEL HMG-CoA REDUCTASE INHIBITORS | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1991-09-19 | — | — | WO | disclosed |
| EP-0403487-A4 | NOVEL HMG-COA REDUCTASE INHIBITORS | — | 1991-06-05 | — | — | EP | disclosed |
| US-4996234-A | Anticholesterol agents | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1991-02-26 | — | — | US | disclosed |
| EP-0403487-A1 | NOVEL HMG-CoA REDUCTASE INHIBITORS | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1990-12-27 | — | — | EP | disclosed |
| US-4900754-A | ANTICHOLESTEROL AGENTS | RORER PHARMACEUTICAL CORP. (US) | 1990-02-13 | — | — | US | disclosed |
| US-4863957-A | ANTICHOLESTEROL AGENTS | RORER PHARMACEUTICAL CORPORATION (US) | 1989-09-05 | — | — | US | disclosed |
| WO-1989005639-A1 | NOVEL HMG-CoA REDUCTASE INHIBITORS | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1989-06-29 | — | — | WO | disclosed |
| EP-0011369-B1 | PROCESS FOR PREPARING 3-EXOMETHYLENECEPHAM SULFOXIDES | ELI LILLY AND COMPANY (US) | 1982-03-24 | — | — | EP | disclosed |
| EP-0011369-A1 | Process for preparing 3-exomethylenecepham sulfoxides | ELI LILLY AND COMPANY (US) | 1980-05-28 | — | — | EP | disclosed |
| US-4190724-A | Process for 3-exomethylenecepham sulfoxides | ELI LILLY AND COMPANY (US) | 1980-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257155-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ZAP70, IGF1R, PTK2 | NOS3 3416/4885NOS1 3296/4885NOS2 3643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.